Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal ® ) in glioma patients in China

ConclusionIt can be concluded that 20-mg and 100-mg capsules of TOZ309 are bioequivalent to Temodal® capsules of the same strength under fasting conditions.Trial registrationhttps://www.chinadrugtrials.org.cn/index.html, CTR2017 0122.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research